2016 - earlier

Selected News from the Archive 2012-2016

15 Jan 2014

The NTtotalCAF ELISA is now officially available.

22 June 2012

Since its successful launch the NTCAF ELISA assay has been further developed.

The range of Neurotune’s diagnostic assay to stratify sarcopenia patients is now extended to further body fluids beyond serum. Plasma and urine may also be used for the in vitro assessment of the sarcopenia biomarker CAF (C-terminal Agrin Fragment). For more information see the revised factsheet.

14 May 2012

The ALS Therapy Development Institute Partners with Neurotune to investigate Potential Treatments for Motor Neuron Desease. Partnership aimed at Neuromuscular Junction Strength against Disease Course.

The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig’s desease).

2 March 2012

Neurotune launches the world’s first ELISA based diagnostic assay for C-terminal Agrin Fragments (CAF) in blood.
Neurotune AG, a Swiss biopharmaceutical company, announces the launch of its immunoassay, NTCAF ELISA, the world’s first ELISA based assay for sarcopenia.

5 December 2011

Neurotune AG is Coordinator of an Eurostars funded Project entitled “Early Diagnosis and Monitoring of Renal Diseases” (Acronym: KIDNEY).
The scope of the project is the validation of a new and most effective diagnostic biomarker (RCAF) for the early monitoring of chronic kidney disease with a possible application in the prognosis of kidney transplant and in acute kidney injury.

14 November 2011

Schlieren (Zurich), Switzerland, 14 November 2011. The FDA has granted Neurotune AG an IND for dimiracetam, the company’s lead compound for treatment of neuropathic pain conditions. Neurotune is planning a pivotal study to demonstrate efficacy of dimiracetam in alleviating neuropathic pain in AIDS patients affected with a treatment related symmetrical painful peripheral neuropathy.

23 February 2011

Neurotune receives EU funding for sarcopenia project
Neurotune AG today announced it is leading a consortium of research teams in the DISARCO project, a two-year project focused on developing an immunoassay for the diagnosis of sarcopenia. The consortium has received €720,000 from the European Eurostars Programme to fund the research.

12 January 2011

Der BIO-TECHNOPARK® Schlieren-Zürich ist zusammen mit Neurotune, ETH Zürich, Universität Zürich und der Standortförderung des Kantons Zürich Partner im EU-Projekt HealthTIES.